Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis.

ABSTRACT:

Background

Psoriasis is a chronic systemic inflammatory disease, and hyperuricemia is a common comorbidity in patients with psoriasis. However, there are limited reports on the relationship between serum uric acid levels and biological treatment efficacy. The purposes of this study were to compare the differences in serum uric acid levels between patients with psoriasis and healthy controls and analyze the risk of hyperuricemia.

Methods

A total of 196 patients with psoriasis and 191 age- and sex-matched healthy controls were enrolled in this retrospective cohort study. One hundred and twenty-seven patients with severe psoriasis were treated with biologics. Sixty-eight patients received adalimumab, and 59 patients received secukinumab. Serum uric acid levels were measured at

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC9481430 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature